Next-generation sequencing (NGS) continues to evolve. We are developing in vitro diagnostics (IVDs) and Personalized Cancer Monitoring (PCM™) for solid tumor biomarker identification.
Solid tumor IVDs: FusionPlex® Dx and LiquidPlex™ Dx
(CE-marked for use in European Union jurisdictions)
Invitae’s Anchored Multiplex PCR (AMP™) chemistry is now available as a CE-marked in-vitro diagnostic (IVD) test designed to identify actionable genomic alterations in tissue and blood samples. This test, intended for use as a companion diagnostic, enables broader patient access to the right cancer therapies at the right time.
Get ahead of cancer.
Invitae PCM is a pan-cancer*, tumor-informed liquid biopsy test that uses next-generation sequencing to detect minimal or molecular residual disease (MRD) in solid tumors.
*With exceptions—such as CNS malignancies and sarcomas—this test is not intended to be used in hematological malignancies such as leukemias or lymphomas.